Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT07060807
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- NCT07060807 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on NCT07060807 (patritumab deruxtecan, pegylated liposomal doxorubicin and 5 more in Breast Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on NCT07060807 so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Neoplasms
- Interventions
- Patritumab deruxtecan; Paclitaxel; Nab-paclitaxel; Capecitabine; Pegylated liposomal doxorubicin; Trastuzumab deruxtecan; Rescue Medication
- Arms
- Patritumab Deruxtecan · Experimental
- Treatment of Physician's Choice · Active comparator
- Enrollment
- 1,000 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Daiichi Sankyo
- Start
- Jul 21, 2025
- Primary completion
- Jul 14, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT07060807 · updated Oct 23, 2026